Adaptimmune Therapeutics PLC — Director's Dealing 2019

Jun 28, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-06-27

Reporting Person: Rawcliffe Adrian (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-27	Option to purchase Ordinary Shares	$0.68	A	628872	Acquired	2029-06-27	Ordinary Shares (628872)	Direct
2019-06-27	Option to purchase Ordinary Shares	$0.0013	A	140448	Acquired		Ordinary Shares (140448)	Direct

Footnotes

F1: The exercise price was converted from GBP0.53 based on an exchange rate of $U.S. 1.26828 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 157,218 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the twenty-seventh of each month from July 27, 2020 through May 27, 2022 and 13,119 Ordinary Shares on June 27, 2023.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26828 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 35,112 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the twenty-seventh of each June from June 27, 2021 through June 27, 2023.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.